{
    "2020-11-17": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial",
                "features": {
                    "keywords": [
                        "semaglutide",
                        "superior reduction",
                        "HbA1c",
                        "SUSTAIN FORTE",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}